Trevena, Inc. (TRVN): Price and Financial Metrics


Trevena, Inc. (TRVN)

Today's Latest Price: $2.34 USD

0.03 (-1.27%)

Updated Nov 25 4:00pm

Add TRVN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

TRVN Stock Summary

  • TRVN's price/sales ratio is 121.23; that's higher than the P/S ratio of 97.28% of US stocks.
  • With a year-over-year growth in debt of -52.36%, Trevena Inc's debt growth rate surpasses merely 5.71% of about US stocks.
  • Revenue growth over the past 12 months for Trevena Inc comes in at 1,206.47%, a number that bests 99.37% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Trevena Inc, a group of peers worth examining would be KIN, JG, CERS, MRAM, and PSNL.
  • TRVN's SEC filings can be seen here. And to visit Trevena Inc's official web site, go to www.trevena.com.

TRVN Stock Price Chart Interactive Chart >

Price chart for TRVN

TRVN Price/Volume Stats

Current price $2.34 52-week high $3.68
Prev. close $2.37 52-week low $0.46
Day low $2.28 Volume 2,483,100
Day high $2.38 Avg. volume 4,931,423
50-day MA $2.71 Dividend yield N/A
200-day MA $1.66 Market Cap 367.45M

Trevena, Inc. (TRVN) Company Bio


Trevena Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and intent to commercialize therapeutics for G protein coupled receptors. The company was founded in 2007 and is based in King of Prussia, Pennsylvania.


TRVN Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVN Latest Social Stream


Loading social stream, please wait...

View Full TRVN Social Stream

Latest TRVN News From Around the Web

Below are the latest news stories about Trevena Inc that investors may wish to consider to help them evaluate TRVN as an investment opportunity.

Trevena: Strong Buy After Opioid Approval And Potential Supplementary COVID-19 Value

Trevena (TRVN) recently received FDA approval for OLINVYK, its novel opioid for acute pain management, as well as initiation of an early Phase 1 study of RAS and coagulopathy in Covid-19 patients in the UK. Although the rest of the company's candidates are in Phase 1 trials and a long...

Damien Robbins on Seeking Alpha | August 31, 2020

Trevena +6.4% as Cantor joins bullish analysts on opioid promise

Trevena (TRVN) finished after-hours trading up 6.4% after Cantor Fitzgerald initiated coverage at Overweight, pegged to promise in the company's new painkiller. It's hard to get an approval for new opioids, analyst Brandon Folkes says, but Trevena's new offering Olinvyk is "sufficiently differentiated" to make a mark. "While Olinvyk does...

Seeking Alpha | August 28, 2020

The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical r...

Benzinga | August 11, 2020

The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson's disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDA...

Benzinga | August 7, 2020

The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD ) (FDA approved the emergency use of Abiomed's Impella heart pump in combination with an oxygen machine to treat Covid-19 patients who suffer heart and lung failure) Allovir Inc (NASDAQ: ALVR ) (IPOed Thursday) Alterity Therapeutics Ltd (NASDAQ: ATHE ) ( announced positive preclinical data for its lead drug in Multiple System Atrophy) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Cardiff Oncology Inc (NASDAQ: CRDF ) Cocrystal Pharma Inc (NASDAQ: COCP ) (announced the publication of positive preclinical animal studies of coronavirus antiviral compounds in a medical journal) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Fulgent Genetics Inc (NASDAQ: FLGT ) Hologic, Inc. (NASDAQ: HOLX ) Inari Medical Inc (NA...

Benzinga | August 5, 2020

Read More 'TRVN' Stories Here

TRVN Price Returns

1-mo -1.68%
3-mo 30.73%
6-mo 80.00%
1-year 227.64%
3-year 39.29%
5-year -81.89%
YTD 178.27%
2019 95.56%
2018 -73.13%
2017 -72.79%
2016 -44.00%
2015 75.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6519 seconds.